We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Creo Medical Group Plc | CREO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 18.90 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.90 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 29/1/2025 06:34 by peterrr3 Good to see gold standard Fujifilm giving some more credibility to Creo tech in their US training programhttps://www.g |
Posted at 15/1/2025 07:03 by bloomberg2 Creo Medical Group plc("Creo" the "Company" or the "Group") First robotic-guided lung ablation cases commenceas part of Intuitive collaboration agreement Robotic-guided microwave ablation of cancerous lung tissue now being undertaken at two UK sites Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the "Hospital"). As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive's Ion Endoluminal System and Creo's MicroBlate Flex ablation device to take place under the amended terms of the agreement at the Hospital. The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study1 conducted by Professor Shah. The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year. Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo's MicroBlate Flex alongside Intuitive's Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress." |
Posted at 16/12/2024 07:52 by bloomberg2 Creo Medical Group - Director/PDMR Shareholding #CREO @CreoMedical https://www.voxmarke |
Posted at 12/11/2024 18:28 by parob "The recent announcement of an agreement for the sale of 51% of Creo Medical Europe represents an excellent strategic partnership opportunity for Creo. The partnership will support our continued commercial growth through Creo Europe with access to the wider Micro-Tech product portfolio secured under the Creo Brand. This product range will also be available to Creo's core sales teams globally to complement our advanced energy portfolio. Additionally, we have the potential to secure product registration and co-branding in China with our advanced energy products which will help our APAC growth in the future. "Over the next six to 12 months, we expect to see the continued growth rate of our core sales, driven by Speedboat UltraSlim, but with developing progress in our other product groups. I thank shareholders for their continued support during the period and look forward to providing further updates." |
Posted at 12/11/2024 16:05 by purchaseatthetop Actually I was benchmarking STX and CREO…“Interesting comparisons between STX and CREO. So thanks to Parob for coming to the board to try to upset me. CREO have spent £157m if retained losses getting to losing £10m every six months. Overhead of £40m a year. Sales about £30m. No revenue growth. 47% gross margin. STX have spent about the same of retained losses getting to losing the same amount every six months. Overhead about the same. 250% revenue growth with similar revenue now. same gross margin. Likely £65m plus revenue 2025. STX market cap £21k CREO market cap £75m Certainly seems one is under or overvalued. Very similar in many ways.” Seems like valid analysis. Just checking my investment in STX makes sense. I would not have noticed CREO ever except for Parob coming over to taunt me. But he did. And so I got interested. Happy to be involved in discussions. Good to meet you all. |
Posted at 12/11/2024 12:14 by purchaseatthetop The problem is that it is going nowhereTotal revenue of £15.2m (H1-2023: £15.7m) Gross margin stuck at 47% Losses of £10m each six months. The hope of the 51% strategic sale looks very uncertain We announced on 18 September 2024 that Creo has entered into a binding agreement with Micro-Tech (NL) International B.V., a wholly owned subsidiary of Micro-Tech (Nanjing) ("Micro-Tech") for the sale of 51% of the issued share capital of Creo Medical S.L.U. ("Creo Medical Europe"), a wholly owned subsidiary of Creo, at an equity value of €72m (the "Sale") on a cash-free, debt-free basis. The net proceeds payable to Creo from the Sale (the "Proceeds") will strengthen the Group's balance sheet, enabling us to continue to invest in our core Creo and Kamaptive business and deliver on our commercial and operational objectives. The Proceeds are expected to be approximately €30m, which will be payable in cash on completion. Ongoing shareholder terms have also been agreed which include a future exit framework for Creo. Along with other customary conditions, completion of the Sale is contingent on Micro-Tech obtaining Outbound Direct Investment clearance in China along with Foreign Direct Investment clearances in Spain, France, Belgium and Germany. Whilst there is no certainty as to receipt or timing of receipt of the necessary approvals to enable completion, it is expected that completion will take place during Q1 2025 dependent on these relevant clearances being obtained. Too many future uncertains. |
Posted at 19/10/2024 09:41 by networker I am not aware if CREO made any comments at yesterday's EGM held in Bristol.Here are their recent (official) comments on recent events:- "As you know the Company announced its strategic partnership with Micro-Tech and the intended disposal of a 51% stake in Creo Europe. Unfortunately, Creo Medical wasn’t in a position to arrange the Placing to coincide with the disposal. After the Micro-Tech news was released a broker’s research note was published that restated again the analyst’s view that the Company had a funding requirement, and that they continued to assume that Creo Medical would need additional cash to bridge through to proceeds from the disposal (although less than previously expected given the transaction). Given the current environment of the equity markets this led to a drag on the share price. In addition, since the announcement of the fundraising, there has been an institutional seller in the market (for non-Creo specific reasons), which has caused further downward pressure. At the same time as there has been a lack of buying activity across equity markets generally due to concerns about what might be announced in the upcoming budget. The Company and its advisers are working hard to ensure that this overhang is cleared and that the share price recovers. " |
Posted at 17/10/2024 16:36 by bloomberg2 17 October 2024Creo Medical Group plc("Creo" or the "Company") Result of Retail Offer Further to the announcements dated 30 September 2024 and 4 October 2024 in relation to the Retail Offer, Creo announces that, following the closing of the Retail Offer by BookBuild earlier today, 369,109 Retail Offer Shares will be issued at an Issue Price of 24 pence per Retail Offer Share in connection with the Retail Offer. Consequently, a total of 50,369,109 New Ordinary Shares, comprising 50,000,000 Placing Shares and 369,109 Retail Offer Shares will be issued conditional on the passing of the Resolutions by Shareholders at the General Meeting to be held on 18 October 2024. Admission, settlement and dealings Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place at 8:00 a.m. on 21 October 2024 and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on 21 October 2024 or such later time and/or date as the Joint Bookrunners and the Company agree (being in any event no later than 8.00 a.m. on 11 November 2024). The New Ordinary Shares, when issued, will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Capitalised terms used but not defined in this announcement have the same meanings as set out in the circular to Shareholders dated 1 October 2024. For further information please contact: Creo Medic |
Posted at 18/9/2024 20:17 by dr biotech Yeah, whilst buying shares is always a risk, the major risk here has passed. Now they just have to prove they can sell their core products.I'm not on twitter, but some chinese guy has posted this (in chinese). Doesn't add a lot but its written from their point of view Nanwei Medical: Announcement on the purchase of 51% equity of Creo Medical S.L.U. [Sun] Basic situation: It is planned to use its own funds to purchase 51% equity of the target company CME through Nanwei Holland. The estimated transaction amount of this transaction is not more than 36.72 million euros (equivalent to approximately RMB 289.4821 million). After the completion of this transaction, the company will hold 51% equity of CME through Nanwei Holland. [Sun] Target company: A wholly-owned subsidiary of Creo, it is a channel company for the sales of medical device products. Its distribution products include Creo's self-developed products and medical device products in the fields of digestion, urology, respiratory, disposable endoscopes, etc. produced by other related medical device companies. Among them, endoscopic consumables and disposable endoscopes account for nearly 70% of the target company's revenue in 2023. The main business is concentrated in Western Europe, covering the United Kingdom, Spain, France, Germany, Belgium, Luxembourg and other countries. The revenue in 2023/2024H1 is 31.942 million/16.593 million euros, and the net profit is 3.468 million/1.574 million euros respectively. [Sun] Acquisition price: Combining the income method and the market value of the original shareholder Creo, the equity value of the target company is finally determined to be 72 million euros after friendly negotiation between the two parties. Valuation calculation: Referring to the content of the announcement, the PE of the target company in 2023 corresponding to this acquisition is about 21 times, and the PS is about 2.25 times. [Sun] Transaction funds: The funds for this transaction come from the company's own funds. As of June 30, 2024, the company's asset-liability ratio is 14.81%, and the company's monetary funds are 122,329.27 million yuan. The transaction amount accounts for about 23.66% of the company's monetary funds. |
Posted at 04/3/2024 14:57 by someuwin New Edison Update:Creo Medical Clinical update MicroBlate Flex progresses with first robotics use Creo Medical has marked another milestone in advancing utility of its electrosurgical devices with the first use of its MicroBlate Flex device in a robotic-guided lung tissue ablation procedure (as part of an ongoing clinical study). Although not disclosed by the company, we believe this procedure was performed on Creo’s Kamaptive technology partner Intuitive Surgical’s ION bronchoscopy-focused robotics platform. Proving and expanding compatibility with robotic platforms has been an overarching goal for Creo and we see this as a notable step towards achieving this. The successful procedure also bodes well for the company’s partnership with Intuitive Surgical, which holds an estimated 57% market share in robotic surgical systems and has an installed base of 534 ION systems, indicative of the sizeable market opportunity for Creo. For reference the lung cancer therapeutic market size is estimated at $28bn in 2022 and is expected to reach c $60bn by 2032. MicroBlate Flex is a flexible, small diameter microwave ablation device designed for minimally-invasive soft tissue ablation. The device received FDA 510(k) clearance in 2021 (CE mark received in 2020) and is currently being evaluated for safety and feasibility in the treatment of lung lesions as part of a muti-site, post-market clinical study (announced in March 2023). The first-in-human procedure was performed in May 2023 by principal investigator, Professor Pallav L Shah, at the Royal Brompton Hospital in London, and this latest update marks the first robotics-assisted procedure using MicroBlate Flex. The procedure was used to ablate a 27mm cancerous nodule from a patient’s lung, in less than three minutes. Robotics-assisted procedures are a coveted goal in cancer treatment, given the greater precision rates and ability to excise small and hard-to-reach nodules and tumours using minimally invasive methods, greatly improving recovery rates and reducing hospitalisation expenses. The said procedure using MicroBlate Flex was performed in the same sitting as a diagnostic procedure, highlighting the utility of such systems in developing more efficient patient care and improving outcomes. We believe the procedure was conducted using Creo’s Kamaptive technology partner Intuitive Surgical’s ION robotics platform, with an installed base of 534 robots (including at the Royal Brompton Hospital) and 54,000 procedures conducted in 2023. Creo signed a multi-year collaboration with Intuitive Surgical in May 2022 and MicroBlate Flex’s utility with the ION robotics system appears to be the first of potential additional collaborations. Should the collaboration roll-over to include Intuitive’s da Vinci systems (installed base of 8,606 systems), the market opportunity can be materially larger. We note that Creo is entitled to milestone and royalty payments as part of the collaboration (c £1.8m licensing fee in 2023). We view this as an exciting development and await further updates from the company. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
